SCHEMBL21821710

SCHEMBL21821710

O=C1CC(c2ccccc2C2CC2)CC(=O)C1=CNCCN1CCN(CCO)CC1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SLC18A3 Q16572 1/20 0.39
▸ HTR2C P28335 3/20 0.36
▸ MAPT P10636 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ HTR1A P08908 2/20 0.35
▸ ADRA1B P35368 1/20 0.35
▸ HTR6 P50406 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.35
▸ DRD3 P35462 2/20 0.34
▸ HTT P42858 1/20 0.34
▸ MAPK1 P28482 2/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ KDM1A O60341 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ HK1 P19367 1/20 0.33
▸ HKDC1 Q2TB90 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21821934 0.89 L3MBTL1 (0.41) SLC18A3HTR2CMAPTNPSR1ALDH1A1
SCHEMBL21821570 0.88 LMNA (0.42) SLC18A3HTR2CMAPTNPSR1HTR1A
SCHEMBL21821628 0.86 RBP4 (0.41) DRD3MAPK1LMNA
SCHEMBL21821591 0.86 SLC18A3 (0.50) SLC18A3ADRA1BALDH1A1KDM1A
SCHEMBL21821636 0.85 HTR6 (0.37) HTR6
SCHEMBL22111728 0.85 HTR1A (0.34) HTR2CMAPTNPSR1HTR1AHTR6
SCHEMBL22111730 0.85 MAP1LC3B (0.48) DRD3
SCHEMBL21821789 0.84 ADRA2A (0.38) MAPTNPSR1HTR1AHTR6HTT
SCHEMBL22111701 0.84 HTR1A (0.39) SLC18A3MAPTNPSR1HTR1AMAPK1
SCHEMBL21821610 0.84 TP53 (0.38) ALDH1A1DRD3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3632903-B1 COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF WIGEN BIOMEDICINE TECH SHANGHAI CO LTD (CN) 2023-10-11 — — EP disclosed
EP-3632903-B1 COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF WIGEN BIOMEDICINE TECH SHANGHAI CO LTD (CN) 2023-10-11 — — EP disclosed
US-11319303-B2 Compound used as autophagy regulator, and preparation method therefor and uses thereof Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) 2022-05-03 — — US disclosed
US-11319303-B2 Compound used as autophagy regulator, and preparation method therefor and uses thereof Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) 2022-05-03 — — US disclosed
US-20200190066-A1 COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) 2020-06-18 — — US disclosed
US-20200190066-A1 COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) 2020-06-18 — — US disclosed
EP-3632903-A1 COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF Wigen Biomedicine Technology (Shanghai) Co., Ltd. (CN) 2020-04-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11319303-B2 Compound used as autophagy regulator, and preparation method therefor and uses thereof ATG7, SQSTM1, BECN1 SLC18A3 2277/4885HTR2C 3931/4885MAPT 763/4885
US-20200190066-A1 COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF ATG7, SQSTM1, BECN1 SLC18A3 2277/4885HTR2C 3931/4885MAPT 763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback